By Christoper Cheney Hospitals need time to prepare for the proposed federal Comprehensive Care for Joint Replacement bundled payment model, says the American Hospital Association. But Meriter Hospital says “Bring it on!,” citing lower costs and better outcomes from its work in
All News
By Max Green More than half of the physicians who bill Medicare in the U.S. are currently being penalized 1 percent of their 2015 payments as a result of the meaningful use program, according to Steven J. Stack, MD, president
WALTHAM, Mass., Oct. 1, 2015 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be participating in four upcoming conferences. 18th Annual
Flexion Therapeutics, Inc. (NASDAQ:FLXN) has lost 23.72% during the past week and dropped 46.87% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 24.51%. Flexion
MINNEAPOLIS — When compared with conservative treatments, operative treatments of adult spinal deformities result in better health-related quality of life outcomes in patients who have any deformity types, according to a speaker here. Shay Bess, MD, said the same pattern was
By Laura Dyrda Ellipse Technologies’ MAGnetic Expansion Control spinal bracing and distraction system has treated more than 2,000 patients. Here are five quick notes: 1. More than 25 percent of the 2,000 patients treated received care in 2015. This shows the technologies’
By Laura Dyrda A new study published in Spine examines the association between perioperative vitamin D levels and non-union rates after elective spinal fusion. There were 133 patients involved in the study with the cervical spine fused in 49 percent of the patients and
By Kenneth Eby Conmed Corp director and an insider Charles Farkas in the last few days paid for 292 company shares having a worth of $13,939 at the average share price of $47.7. This deal decreased his ownership of the
Kuros Biosurgery AG, a biotechnology company developing novel biomaterials and bioactive-biomaterial combination products, today announces that it has been chosen to make two podium presentations on its novel orthobiologics at the upcoming 2015 Orthope…
© 2025 MedDeviceJobs.com Powered by Careerleaf
v.4.6.1